Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeu (NQ: ALDX )

10.90 USD UNCHANGED
Streaming Delayed Price Updated: 5:42 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aldeyra Therapeu

< Previous 1 2 3 4 5 6 7 8 Next >
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August: 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today... 
From Business Wire News Releases
Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior and... 
From Business Wire News Releases
Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment.... 
From Business Wire News Releases
Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics to Present at the Jefferies Virtual Healthcare Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference... 
From Business Wire News Releases
Thinking about buying stock in RumbleON Inc, Aldeyra Therapeutics, Vaxart Inc, VBI Vaccines, or Remark Holdings?
InvestorsObserver issues critical PriceWatch Alerts for RMBL, ALDX, VXRT, VBIV, and MARK. 
From PR Newswire
Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA Coron
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Wednesday, May 20, 2020 to provide a COVID-19 development update. 
From Business Wire News Releases
Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First-Quarter 2020 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with... 
From Business Wire News Releases
Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for... 
From Business Wire News Releases
Aldeyra Therapeutics Reports Full-Year 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative... 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Fourth-Quarter and Full-Year 2019 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics to Present at the Oppenheimer & Co. 30th Annual Healthcare Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today will host the 2020 Research & Development Day (R&D Day) with investors and financial analysts in New York City to present recent clinical... 
From Business Wire News Releases
Aldeyra Therapeutics to Host 2020 Research & Development Day
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board
Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board 
From Business Wire News Releases
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Appoints Nancy Miller-Rich to Board of Directors
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Tuesday, December 3, 2019, to provide top-line results from Part 1 of the adaptive Phase 3... 
From Business Wire News Releases
Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.